Skip to main content
Premium Trial:

Request an Annual Quote

Illumina's Q1 Revenues Rise 148 Percent as R&D Nearly Doubles; Solexa Buy Widens Loss

NEW YORK (GenomeWeb News) — Illumina today said first-quarter revenues increased 148 percent as R&D spending nearly doubled and the company posted a $300 million net loss affected by acquisition-related charges.
 
Total receipts for the three months ended March 31 increased to $72.2 million from $29.1 million year over year.
 
Product revenues nearly tripled, rising to $61.2 million from $21.3 million, while service and other revenue more than doubled to $10.8 million from $5.2 million year over year.
 
R&D spending almost doubled to $16 million from $8.2 million in the year-ago period.
 
Illumina said net loss swelled to $298 million from $104,000 in the year-ago period. The $600-million acquisition of Solexa in late January, which included a $303 million charge, had the greatest impact on the loss, Illumina said.
  
Illumina said it had around $326 million in cash, cash equivalents, and short-term investments as of March 31.
 
The company said it expects 2007 revenue to be between $305 million and $315 million.
 
Second-quarter revenues are expected to be between $74 million and $78 million.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.